Identification of mCMQ069, a novel antimalarial with potential for a single-dose cure and/or 28-day chemoprevention
Anil K. Sen Gupta, James Pedroarena, Armen Nazarian, Jenya Antonova-Koch, Frank Weiss, Krittikorn Kümpornsin, Victor Chi, Ashley K. Woods, Kyoung-Jin Lee, Sean B. Joseph, Shuangwei Li, Jason Brittain, Eugenio de Hostos, James P. Duffy, Anne E. Cooper, Peter G. Schultz, Case W. McNamara, Arnab K. Chatterjee · bioRxiv (Cold Spring Harbor Laboratory) · 2024
In efforts towards eliminating malaria, a discovery program was initiated to identify a novel antimalarial using KAF156 as a starting point. Following the most recent TCP/TPP guidelines, we have identified mCMQ069 with a predicted single oral dose for treatment (∼40-106 mg) and one-month chemoprevention (∼96-216 mg). We have improved unbound MPC and predicted human clearance by 18-fold and 10-fold respectively when compared to KAF156.